Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome

We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent (18)F-Fluorodeoxyglucose ([(18)F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month th...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgard, Caroline, Rosar, Florian, Khreish, Fadi, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947295/
https://www.ncbi.nlm.nih.gov/pubmed/35328232
http://dx.doi.org/10.3390/diagnostics12030680
Descripción
Sumario:We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent (18)F-Fluorodeoxyglucose ([(18)F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Post-therapeutic [(18)F]FDG PET/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient’s symptoms and decrease in serum tryptase level. [(18)F]FDG PET/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis.

Ejemplares similares